Table 1.
Demographic and clinical characteristics of TAA patients (n = 40)
| Demographics | |
| Male/female | 28 (70 %)/12 (30 %) |
| Age at MRI (years) | 59 ± 13 |
| Clinical characteristics | |
| Height (cm) | 180 ± 10 |
| Body mass index (kg/m2) | 27 ± 4 |
| Body surface area (m2) | 2.1 ± 0.2 |
| Brachial blood pressure (mmHg) | |
| Systolic | 134 ± 20 |
| Diastolic | 79 ± 11 |
| Heart rate (beats/minute) | 66 ± 10 |
| MRI assessed LV dimensions and function | |
| EDV (ml) | 164 ± 38 |
| EDV/BSA (ml/m2) | 80 ± 19 |
| ESV (ml) | 69 ± 23 |
| ESV/BSA (ml/m2) | 34 ± 12 |
| Ejection fraction (%) | 62 ± 5 |
| Cardiovascular risk factors | |
| Hypertensiona | 27 (68 %) |
| Current smoker | 7 (18 %) |
| Hypercholesterolaemiab | 16 (40 %) |
| Diabetes mellitus | 1 (3 %) |
| Obesityc | 7 (18 %) |
| Previous myocardial infarction | 4 (10 %) |
| Cardiovascular medication | |
| β-blocker | 17 (58 %) |
| ACE inhibitor | 21 (53 %) |
| Anticoagulants | 16 (40 %) |
| Statins | 13 (33 %) |
Data are presented as number (percentage) or as mean ± standard deviation.
LV left ventricular, EDV end-diastolic volume, ESV end-systolic volume, BSA body surface area.
aSystolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or use of antihypertensive medication.
bSerum total cholesterol ≥ 230 mg/dl or serum triglycerides ≥ 200 mg/dl or treatment with lipid-lowering drugs.
cBody mass index ≥ 30 kg/m2.